This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accuray's CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Accuray Incorporated (ARAY)

Morgan Stanley Global Healthcare Conference

September 10, 2012 11:10 a.m. ET


Euan Thomson - President & Chief Executive Officer


Steve Beuchaw - Morgan Stanley


Steve Beuchaw - Morgan Stanley

Thank you all for joining us here. I am Steve Beuchaw from the Morgan Stanley medtech team. It’s my pleasure to welcome Accuray this morning. I have Euan Thomson, CEO of the company and Tom Rathjen from Investor Relations. Before we begin though, I do want to point out that all important disclosures including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at researchdisclosures. It’s a riveting read. You should check it out.

Guys, so we had a good conversation last week. We had an opportunity to see the results for the quarter and the outlook for the year. I think the surprise coming out of the quarter of course was the comments around ASTRO. Expectations for ASTRO. I would like to start on innovation. Given how much lately we have all been worried, not specifically with Accuray but with the macro economy and the world of reimbursement. But again, let's start with innovation. So you have been pretty upfront about the importance of the meeting but less clear exactly on what we expect to see there.

So how are you today trying to outline for investors, the importance of ASTRO? What should we be thinking about? A revolutionary patient treatment opportunity, the financial impact. How are you framing it?

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.31 -0.91%
FB $118.16 0.62%
GOOG $696.76 0.64%
YHOO $35.84 -0.47%
TSLA $229.74 -1.10%


Chart of I:DJI
DOW 17,683.28 -67.63 -0.38%
S&P 500 2,054.23 -9.14 -0.44%
NASDAQ 4,739.8820 -23.3420 -0.49%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs